Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the slow progression of pathological processes that lead to dementia. The diagnosis of AD is traditionally associated with highly invasive and costly procedures such as cerebrospinal fluid (CSF) analysis or expensive neuroimaging techniques like PET scans—methods that are usually inaccessible, costly, and unsuitable for large-scale population screening. Recently, there has been a rapid increase in studies demonstrating the ability of blood-based biomarkers (BBBs) to detect pathological changes in the brain. These include markers of abnormal protein metabolism, glial cell activation, and neuronal damage. This review aims to discuss the current literature data on the role of BBBs in the differential diagnosis of AD and other dementias. Particular attention is paid to the assessment of diagnostic accuracy and potential clinical applications of such biomarkers as Aβ 42/ Aβ 40 plasma amyloid beta ratio, phosphorylated tau181, phosphorylated tau217, phosphorylated tau231, neurofilament light chain, and glial fibrillary acidic protein. Moreover, this study highlights recent advances in the field, including innovative approaches to biomarker discovery and validation, such as single-molecule array technology and artificial intelligence-assisted multimodal analysis. Although some methodological and ethical issues remain to be addressed, BBBs appear to be a promising tool for improving the early diagnosis of AD and differentiating it from other neurodegenerative diseases, in its preclinical and prodromal stages which may contribute to a better outcome of management. J Bangladesh Coll Phys Surg 2026; 44: 298-306
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: